The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) is a huge mover today! About 196,108 shares traded hands. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 31.80% since March 8, 2016 and is uptrending. It has outperformed by 22.48% the S&P500.
The move comes after 9 months negative chart setup for the $1.64 billion company. It was reported on Oct, 11 by Barchart.com. We have $41.12 PT which if reached, will make NASDAQ:SAGE worth $82.00 million less.
Analysts await SAGE Therapeutics Inc (NASDAQ:SAGE) to report earnings on November, 3. They expect $-1.11 earnings per share, down 32.14% or $0.27 from last year’s $-0.84 per share. After $-1.08 actual earnings per share reported by SAGE Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.78% negative EPS growth.
SAGE Therapeutics Inc (NASDAQ:SAGE) Ratings Coverage
Out of 9 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 7 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 78% are positive. SAGE Therapeutics has been the topic of 10 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The company was initiated on Thursday, June 23 by H.C. Wainwright. The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) earned “Neutral” rating by Goldman Sachs on Wednesday, March 30. Lake Street initiated SAGE Therapeutics Inc (NASDAQ:SAGE) on Friday, March 11 with “Buy” rating. As per Wednesday, June 29, the company rating was initiated by BMO Capital Markets. The stock has “Sell” rating given by Chardan Capital Markets on Tuesday, May 24. The firm earned “Outperform” rating on Tuesday, September 13 by Raymond James. The stock has “Buy” rating given by JP Morgan on Thursday, September 3. Leerink Swann maintained SAGE Therapeutics Inc (NASDAQ:SAGE) on Thursday, September 3 with “Buy” rating.
According to Zacks Investment Research, “SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.51 in Q2 2016. Its down 0.73, from 2.24 in 2016Q1. The ratio worsened, as 28 funds sold all SAGE Therapeutics Inc shares owned while 27 reduced positions. 23 funds bought stakes while 60 increased positions. They now own 29.30 million shares or 2.83% more from 28.49 million shares in 2016Q1.
The Texas-based Utd Svcs Automobile Association has invested 0% in SAGE Therapeutics Inc (NASDAQ:SAGE). Morgan Stanley accumulated 0% or 71,788 shares. Voya Invest Mngmt Limited Liability Company has invested 0.03% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Quantbot Technologies Lp holds 0.01% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE) for 2,895 shares. Legal And General Gp Public Limited Co last reported 5,414 shares in the company. Parametric Portfolio Associates Ltd Limited Liability Company, a Washington-based fund reported 17,686 shares. Los Angeles Capital Mngmt Equity Research Inc has 6,890 shares for 0% of their US portfolio. Brown Brothers Harriman Com accumulated 92 shares or 0% of the stock. Deutsche Natl Bank Ag has 417,012 shares for 0.01% of their US portfolio. Goldman Sachs has invested 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Bnp Paribas Arbitrage Sa holds 0% or 1,034 shares in its portfolio. Moreover, Visium Asset Mgmt L P has 0.02% invested in SAGE Therapeutics Inc (NASDAQ:SAGE) for 7,395 shares. Metropolitan Life Insur Ny has invested 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). New Leaf Venture Prns Llc has 156,958 shares for 4.07% of their US portfolio. Ladenburg Thalmann Finance Inc holds 0% or 16 shares in its portfolio.
Insider Transactions: Since April 19, 2016, the stock had 0 insider purchases, and 6 sales for $55.15 million net activity. Third Rock Ventures II – L.P. also sold $26.56M worth of SAGE Therapeutics Inc (NASDAQ:SAGE) shares. $880,000 worth of SAGE Therapeutics Inc (NASDAQ:SAGE) was sold by Robichaud Albert on Tuesday, July 12. Shares for $798,000 were sold by Kanes Stephen on Tuesday, April 19. IGUCHI KIMI sold $102,325 worth of stock or 2,500 shares. 850,000 shares were sold by STARR KEVIN P, worth $26.56 million on Monday, May 16.
More important recent SAGE Therapeutics Inc (NASDAQ:SAGE) news were published by: Fool.com which released: “Here’s Why SAGE Therapeutics Inc. Is Surging Today” on July 12, 2016, also Marketwatch.com published article titled: “Sage Therapeutics stock rises 12% after FDA designates drug a ‘breakthrough …”, Valuewalk.com published: “SAGE Therapeutics Inc (SAGE) – Debunking Asclepia Capital” on April 01, 2016. More interesting news about SAGE Therapeutics Inc (NASDAQ:SAGE) was released by: Valuewalk.com and their article: “SAGE Therapeutics Inc (SAGE) Overhyped Lead Drug Headed for Failure â€“ Kerrisdale” with publication date: March 23, 2016.
SAGE Company Profile
SAGE Therapeutics, Inc., incorporated on April 16, 2010, is a clinical-stage biopharmaceutical company. The Firm is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Firm is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.